Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:APTNASDAQ:INGNNASDAQ:LUNGNASDAQ:TLSI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTAlpha Pro Tech$4.45+2.8%$4.87$4.06▼$6.44$48.39M0.3335,321 shs23,281 shsINGNInogen$7.15+3.9%$7.65$6.40▼$13.33$192.24M1.48238,816 shs187,675 shsLUNGPulmonx$5.17+3.6%$6.85$4.15▼$10.01$200.83M0.61317,259 shs285,268 shsTLSITriSalus Life Sciences$5.65-1.2%$5.51$3.50▼$10.24$172.29M0.4944,429 shs19,696 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTAlpha Pro Tech+2.77%+2.65%-11.00%-17.90%-27.52%INGNInogen+3.92%+4.84%-1.38%-37.50%+1.42%LUNGPulmonx+3.61%+14.38%-24.85%-15.38%-31.25%TLSITriSalus Life Sciences-1.22%-1.57%0.00%+9.07%-44.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTAlpha Pro TechN/AN/AN/AN/AN/AN/AN/AN/AINGNInogen3.2558 of 5 stars1.05.00.03.93.11.71.3LUNGPulmonx2.8779 of 5 stars3.43.00.00.03.52.50.6TLSITriSalus Life Sciences3.2772 of 5 stars3.64.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTAlpha Pro Tech 0.00N/AN/AN/AINGNInogen 2.00Hold$7.00-2.10% DownsideLUNGPulmonx 2.75Moderate Buy$12.75146.62% UpsideTLSITriSalus Life Sciences 3.20Buy$11.56104.65% UpsideCurrent Analyst Ratings BreakdownLatest APT, LUNG, INGN, and TLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/28/2025TLSITriSalus Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/10/2025LUNGPulmonxJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy3/10/2025LUNGPulmonxMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Equal Weight3/10/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy3/10/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$17.00 ➝ $17.002/26/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/13/2025TLSITriSalus Life SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.001/30/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTAlpha Pro Tech$57.84M0.84$0.35 per share12.80$5.29 per share0.84INGNInogen$335.71M0.57N/AN/A$8.79 per share0.81LUNGPulmonx$83.79M2.48N/AN/A$3.09 per share1.67TLSITriSalus Life Sciences$29.43M5.85N/AN/A($0.98) per share-5.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTAlpha Pro Tech$4.19M$0.3612.03∞N/A6.99%6.70%5.76%N/AINGNInogen-$102.45M-$1.52N/AN/AN/A-15.89%-27.38%-16.77%5/7/2025 (Estimated)LUNGPulmonx-$60.84M-$1.44N/AN/AN/A-67.31%-55.36%-33.53%4/29/2025 (Estimated)TLSITriSalus Life Sciences-$59.04M-$1.33N/AN/AN/A-206.24%N/A-236.83%5/21/2025 (Estimated)Latest APT, LUNG, INGN, and TLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025TLSITriSalus Life Sciences-$0.20N/AN/AN/AN/AN/A5/7/2025Q1 2025INGNInogen-$0.52N/AN/AN/A$79.57 millionN/A5/7/2025Q1 2025LUNGPulmonx-$0.37N/AN/AN/A$22.03 millionN/A3/27/2025Q4 2024TLSITriSalus Life Sciences-$0.35-$0.35N/A-$0.40$8.12 million$8.26 million2/19/2025Q4 2024LUNGPulmonx-$0.45-$0.33+$0.12-$0.33$22.29 million$23.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTAlpha Pro TechN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ATLSITriSalus Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTAlpha Pro TechN/A19.0011.21INGNInogenN/A2.662.34LUNGPulmonx0.407.706.77TLSITriSalus Life SciencesN/A2.402.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTAlpha Pro Tech22.69%INGNInogen89.94%LUNGPulmonx91.04%TLSITriSalus Life Sciences2.58%Insider OwnershipCompanyInsider OwnershipAPTAlpha Pro Tech14.00%INGNInogen1.46%LUNGPulmonx6.80%TLSITriSalus Life Sciences32.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTAlpha Pro Tech12010.87 million9.46 millionOptionableINGNInogen1,03026.89 million23.58 millionOptionableLUNGPulmonx25040.25 million37.24 millionOptionableTLSITriSalus Life Sciences10630.49 million20.49 millionNot OptionableAPT, LUNG, INGN, and TLSI HeadlinesRecent News About These CompaniesTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from BrokeragesApril 24 at 2:21 AM | americanbankingnews.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Rating of "Buy" by BrokeragesApril 21, 2025 | marketbeat.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock?April 9, 2025 | zacks.comTriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on MondayMarch 31, 2025 | marketbeat.comTriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still RisksMarch 30, 2025 | seekingalpha.comCanaccord Genuity Group Reiterates Buy Rating for TriSalus Life Sciences (NASDAQ:TLSI)March 29, 2025 | marketbeat.comTriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Hits EstimatesMarch 28, 2025 | marketbeat.comTrisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetrationMarch 27, 2025 | msn.comTriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays PessimisticMarch 27, 2025 | msn.comTriSalus Life Sciences, Inc. (TLSI) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comTriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue EstimatesMarch 27, 2025 | zacks.comTriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | businesswire.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Rating of "Buy" from AnalystsMarch 25, 2025 | marketbeat.com3 Stocks With Robust Growth Outlooks Insiders Are Buying (TLSI)February 19, 2025 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases $33,900.00 in StockFebruary 7, 2025 | insidertrades.comTrisalus Life Sciences CFO buys $33,900 in common stockFebruary 6, 2025 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Purchases 5,030 SharesFebruary 1, 2025 | insidertrades.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Buys 4,826 SharesJanuary 30, 2025 | insidertrades.comTriSalus Life Sciences: Strong Q4 2024 Performance and Promising 2025 Outlook Drive Buy RatingJanuary 25, 2025 | markets.businessinsider.comTriSalus reports 59% annual revenue growth in 2024January 23, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Buffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentOccidental’s Billion-Dollar Carbon Credit Plan Takes ShapeBy Jea Yu | March 26, 2025View Occidental’s Billion-Dollar Carbon Credit Plan Takes Shape3 Energy Stock Winners Even as Oil Prices PlungeBy Chris Markoch | April 11, 2025View 3 Energy Stock Winners Even as Oil Prices PlungeBuffett Loves Occidental Petroleum—Should You? 4 Pros, 3 ConsBy Jea Yu | April 15, 2025View Buffett Loves Occidental Petroleum—Should You? 4 Pros, 3 ConsAPT, LUNG, INGN, and TLSI Company DescriptionsAlpha Pro Tech NYSE:APT$4.48 +0.15 (+3.46%) As of 04/24/2025 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through Disposable Protective Apparel and Building Supply segments. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap and housewrap accessories, including window and door flashing, and seam tape, synthetic roof underlayment, and self-adhered roof underlayment, as well as other woven material. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.Inogen NASDAQ:INGN$7.15 +0.27 (+3.92%) As of 04/24/2025 04:00 PM EasternInogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.Pulmonx NASDAQ:LUNG$5.17 +0.18 (+3.61%) As of 04/24/2025 04:00 PM EasternPulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.TriSalus Life Sciences NASDAQ:TLSI$5.65 -0.07 (-1.22%) As of 04/24/2025 04:00 PM EasternTriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
